Neuroglee gets $2.3 million to develop digital therapeutics for neurodegenerative diseases

There are now about 50 million people with dementia globally, a number the World Health Organization expects to triple by 2050. Alzheimer’s is the leading cause of dementia and caregivers are often overwhelmed, without enough support.

Neuroglee, a Singapore-based health tech startup, wants to help with a digital therapeutic platform created to treat patients in the early stages of the disease. Founded this year to focus on neurodegenerative diseases, Neuroglee announced today it has raised $2.3 million in pre-seed funding.

The round was led by Eisai Co., one of Japan’s largest pharmaceutical companies, and Kuldeep Singh Rajput, the founder and chief executive officer of predictive healthcare startup Biofourmis.

SoftBank Vision Fund 2 leads $100 million Series C in digital therapeutics company Biofourmis

Neuroglee’s prescription digital therapy software for Alzheimer’s, called NG-001, is its main product. The company plans to start clinical trials next year. NG-001 is meant to complement medication and other treatments, and once it is prescribed by a clinician, patients can access its cognitive exercises and tasks through a tablet.

The software tracks patients’ progress, such as the speed of their fingers and the time it takes to complete an exercise, and delivers personalized treatment programs. It also has features to address the mental health of patients, including one that shows images that can bring up positive memories, which in turn can help alleviate depression and anxiety when used in tandem with other cognitive behavioral therapy techniques.

For caregivers and clinicians, NG-001 helps them track patient progress and their compliance with other treatments, like medications. This means that healthcare providers can work closely with patients even remotely, which is especially important during the COVID-19 pandemic.

Neuroglee founder and CEO Aniket Singh Rajput told TechCrunch that its first target markets for NG-001 are the United States and Singapore, followed by Japan. NG-001 needs to gain regulatory approval in each country, and it will start by seeking U.S. Food and Drug Administration clearance.

Once it launches, clinicians will have two ways to prescribe NG-001, through their healthcare provider platform or an electronic prescription tool. A platform called Neuroglee Connect will give clinicians, caregivers and patients access to support and features for reimbursement and coverage.

As Alzheimer’s costs soar, startups like Neurotrack raise cash to diagnose and treat the disease

from https://techcrunch.com/2020/12/02/neuroglee-gets-2-3-million-to-develop-digital-therapeutics-for-neurodegenerative-diseases/